183 related articles for article (PubMed ID: 31242860)
1. Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study.
Ahimbisibwe C; Kwizera R; Ndyetukira JF; Kugonza F; Sadiq A; Hullsiek KH; Williams DA; Rhein J; Boulware DR; Meya DB
BMC Infect Dis; 2019 Jun; 19(1):558. PubMed ID: 31242860
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory induction phase treatment of cryptococcal meningitis in HIV integrated primary care clinics, Yangon, Myanmar.
Warrell CE; Macrae C; McLean ARD; Wilkins E; Ashley EA; Smithuis F; Tun NN
BMC Infect Dis; 2021 Apr; 21(1):375. PubMed ID: 33882845
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
[TBL] [Abstract][Full Text] [Related]
4. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
Lawrence DS; Youssouf N; Molloy SF; Alanio A; Alufandika M; Boulware DR; Boyer-Chammard T; Chen T; Dromer F; Hlupeni A; Hope W; Hosseinipour MC; Kanyama C; Lortholary O; Loyse A; Meya DB; Mosepele M; Muzoora C; Mwandumba HC; Ndhlovu CE; Niessen L; Schutz C; Stott KE; Wang D; Lalloo DG; Meintjes G; Jaffar S; Harrison TS; Jarvis JN
Trials; 2018 Nov; 19(1):649. PubMed ID: 30470259
[TBL] [Abstract][Full Text] [Related]
5. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.
Eshun-Wilson I; Okwen MP; Richardson M; Bicanic T
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009012. PubMed ID: 30039850
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa.
Meiring S; Fortuin-de Smidt M; Kularatne R; Dawood H; Govender NP;
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004865. PubMed ID: 27467556
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
Joly V; Aubry P; Ndayiragide A; Carrière I; Kawa E; Mlika-Cabanne N; Aboulker JP; Coulaud JP; Larouze B; Yeni P
Clin Infect Dis; 1996 Sep; 23(3):556-62. PubMed ID: 8879780
[TBL] [Abstract][Full Text] [Related]
8. Treatment for HIV-associated cryptococcal meningitis.
Tenforde MW; Shapiro AE; Rouse B; Jarvis JN; Li T; Eshun-Wilson I; Ford N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD005647. PubMed ID: 30045416
[TBL] [Abstract][Full Text] [Related]
9. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Jarvis JN; Lawrence DS; Meya DB; Kagimu E; Kasibante J; Mpoza E; Rutakingirwa MK; Ssebambulidde K; Tugume L; Rhein J; Boulware DR; Mwandumba HC; Moyo M; Mzinganjira H; Kanyama C; Hosseinipour MC; Chawinga C; Meintjes G; Schutz C; Comins K; Singh A; Muzoora C; Jjunju S; Nuwagira E; Mosepele M; Leeme T; Siamisang K; Ndhlovu CE; Hlupeni A; Mutata C; van Widenfelt E; Chen T; Wang D; Hope W; Boyer-Chammard T; Loyse A; Molloy SF; Youssouf N; Lortholary O; Lalloo DG; Jaffar S; Harrison TS;
N Engl J Med; 2022 Mar; 386(12):1109-1120. PubMed ID: 35320642
[TBL] [Abstract][Full Text] [Related]
10. Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management.
Pastick KA; Nalintya E; Tugume L; Ssebambulidde K; Stephens N; Evans EE; Ndyetukira JF; Nuwagira E; Skipper C; Muzoora C; Meya DB; Rhein J; Boulware DR; Rajasingham R
Med Mycol; 2020 Apr; 58(3):282-292. PubMed ID: 31689712
[TBL] [Abstract][Full Text] [Related]
11. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.
Molloy SF; Kanyama C; Heyderman RS; Loyse A; Kouanfack C; Chanda D; Mfinanga S; Temfack E; Lakhi S; Lesikari S; Chan AK; Stone N; Kalata N; Karunaharan N; Gaskell K; Peirse M; Ellis J; Chawinga C; Lontsi S; Ndong JG; Bright P; Lupiya D; Chen T; Bradley J; Adams J; van der Horst C; van Oosterhout JJ; Sini V; Mapoure YN; Mwaba P; Bicanic T; Lalloo DG; Wang D; Hosseinipour MC; Lortholary O; Jaffar S; Harrison TS;
N Engl J Med; 2018 Mar; 378(11):1004-1017. PubMed ID: 29539274
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.
Bicanic T; Bottomley C; Loyse A; Brouwer AE; Muzoora C; Taseera K; Jackson A; Phulusa J; Hosseinipour MC; van der Horst C; Limmathurotsakul D; White NJ; Wilson D; Wood R; Meintjes G; Harrison TS; Jarvis JN
Antimicrob Agents Chemother; 2015 Dec; 59(12):7224-31. PubMed ID: 26349818
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
Torre D; Banfi G; Tambini R; Speranza F; Zeroli C; Martegani R; Airoldi M; Fiori G
J Infect; 1998 Jul; 37(1):36-8. PubMed ID: 9733375
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.
Livermore J; Howard SJ; Sharp AD; Goodwin J; Gregson L; Felton T; Schwartz JA; Walker C; Moser B; Müller W; Harrison TS; Perfect JR; Hope WW
mBio; 2014 Jan; 5(1):e00725-13. PubMed ID: 24473125
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: a multicentric, randomized controlled trial.
Jadhav MP; Bamba A; Shinde VM; Gogtay N; Kshirsagar NA; Bichile LS; Mathai D; Sharma A; Varma S; Digumarathi R
J Postgrad Med; 2010; 56(2):71-5. PubMed ID: 20622383
[TBL] [Abstract][Full Text] [Related]
16. British HIV Association opportunistic infection guidelines: in defence of amphotericin B deoxycholate.
Bicanic T; Ogden D; Whitney L; Loyse A; Jarvis J
HIV Med; 2012 Nov; 13(10):636-7. PubMed ID: 23051823
[No Abstract] [Full Text] [Related]
17. Alternate-day versus once-daily administration of amphotericin B in the treatment of cryptococcal meningitis: a randomized controlled trial.
Techapornroong M; Suankratay C
Scand J Infect Dis; 2007; 39(10):896-901. PubMed ID: 17852947
[TBL] [Abstract][Full Text] [Related]
18. Burden of acute kidney injury in HIV patients under deoxycholate amphotericin B therapy for cryptococcal meningitis and cost-minimization analysis of amphotericin B lipid complex.
Tuon FF; Florencio KL; Rocha JL
Med Mycol; 2019 Apr; 57(3):265-269. PubMed ID: 29762761
[TBL] [Abstract][Full Text] [Related]
19. Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity.
Falci DR; Lunardi LW; Ramos CG; Bay MB; Aquino VR; Goldani LZ
Clin Infect Dis; 2010 Mar; 50(5):e26-9. PubMed ID: 20121575
[TBL] [Abstract][Full Text] [Related]
20. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.
Leenders AC; Reiss P; Portegies P; Clezy K; Hop WC; Hoy J; Borleffs JC; Allworth T; Kauffmann RH; Jones P; Kroon FP; Verbrugh HA; de Marie S
AIDS; 1997 Oct; 11(12):1463-71. PubMed ID: 9342068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
